In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia

Annals of Hematology

Volumn 87, Issue 1, 2008, Pages 27-33

  Fiegl, Michael ^a   Zimmermann, Inka ^a   Lorenz, Isolde ^a   Hiddemann, Wolfgang ^a   Braess, Jan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AML; Chemotherapy; Cross resistance; Sensitivity

Indexed keywords

CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; IDARUBICIN; MITOXANTRONE; NUCLEOSIDE DERIVATIVE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CELL POPULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEOSIDES; TUMOR CELLS, CULTURED;

EID: 36549009639     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0361-z     Document Type: Article

References (27)

1. SOFTmaxPRO-User manual, 2.4 edn. Molecular Devices Corporation, Sunnyvale, California
2. Andreeff M, Jiang S, Zhang X et al (1999) Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia 13:1881-1892
3. Braess J, Jahns-Streubel G, Schoch C et al (2001) Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 113:975-982
4. Braess J, Schneiderat P, Schoch C et al (2004) Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response. Br J Haematol 126:338-347
5. Braess J, Voss S, Jahns-Streubel G et al (2000) The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 110:170-179
6. Clark PI, Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223-252
7. Estey EH, Thall PF, Cortes JE et al (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98:3575-3583
8. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A (2005) Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369
9. Fonatsch C, Schaadt M, Kirchner H, Diehl V (1980) A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 26:749-756
10. Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875-890
11. Ho AD, Brado B, Haas R, Hunstein W (1991) Etoposide in acute leukemia. Past experience and future perspectives. Cancer 67:281-284
12. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54:1-7
13. Hubeek I, Peters GJ, Broekhuizen R et al (2006) In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica 91:17-23
14. Konopleva M, Zhao S, Hu W et al (2002) The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 118:521-534
15. Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA (1987) A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 5:391-397
16. Levasseur LM, Slocum HK, Rustum YM, Greco WR (1998) Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58:5749-5761
17. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062
18. Norgaard JM, Bukh A, Langkjer ST et al (1998) MDR1 gene expression and drug resistance of AML cells. Br J Haematol 100:534-540
19. Osheroff N, Corbett AH, Robinson MJ (1994) Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol 29B:105-126
20. Robert J, Rigal-Huguet F, Hurteloup P (1992) Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 10:111-116
21. Rowinsky EK, Adjei A, Donehower RC et al (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203
22. Schellens JH, Maliepaard M, Scheper RJ et al (2000) Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 922:188-194
23. Soni N, Meropol NJ, Pendyala L et al (1997) Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. J Clin Oncol 15:766-772
24. Stollmann B, Fonatsch C, Havers W (1985) Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders. Br J Haematol 60:183-196
25. Takashima Y, Matsuyama K (1987) Pharmacokinetic studies of intermediate- to high-dose 1-beta-D-arabinofuranosylcytosine in children with acute leukemia and lymphoma. J Clin Pharmacol 27:330-333
26. Tamm I, Richter S, Oltersdorf D et al (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10:3737-3744
27. Zhao S, Konopleva M, Cabreira-Hansen M et al (2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18:267-275